- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT02166463
Brentuximab vedotina y quimioterapia combinada en el tratamiento de niños y adultos jóvenes con linfoma de Hodgkin en estadio IIB, estadio IIIB, IVA o IVB
Un estudio aleatorizado de fase 3 de brentuximab vedotin (SGN-35) para el linfoma de Hodgkin clásico (cHL) de alto riesgo recién diagnosticado en niños y adultos jóvenes
This phase III trial studies brentuximab vedotin and combination chemotherapy to see how well they work compared to combination chemotherapy alone in treating children and young adults with stage IIB with bulk, stage IIIB, IVA, or IVB Hodgkin lymphoma. Combinations of biological substances in brentuximab vedotin may be able to carry cancer-killing substances directly to Hodgkin lymphoma cells. Chemotherapy drugs, such as doxorubicin hydrochloride, bleomycin sulfate, vincristine sulfate, etoposide, prednisone, and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known if combination chemotherapy is more effective with or without brentuximab vedotin in treating children with high-risk Hodgkin lymphoma.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
- Otro: Laboratory Biomarker Analysis
- Otro: Quality-of-Life Assessment
- Droga: Cyclophosphamide
- Droga: Doxorubicin Hydrochloride
- Droga: Prednisone
- Droga: Vincristine Sulfate
- Otro: Questionnaire Administration
- Droga: Brentuximab Vedotin
- Droga: Etoposide
- Otro: Pharmacological Study
- Biológico: Bleomycin Sulfate
- Droga: Methylprednisolone
Descripción detallada
PRIMARY OBJECTIVE:
I. To assess the event free survival (EFS) of a novel regimen incorporating brentuximab vedotin (Bv; Adcetris) in the chemotherapy backbone of doxorubicin hydrochloride (doxorubicin) (Adriamycin), vincristine sulfate (vincristine), etoposide, prednisone and cyclophosphamide (Bv-AVEPC) in newly diagnosed high-risk classical Hodgkin lymphoma (cHL) compared to those treated with Adriamycin, bleomycin sulfate, vincristine sulfate, etoposide, prednisone, and cyclophosphamide (ABVE-PC).
SECONDARY OBJECTIVES:
I. To determine whether children/young adults with high-risk cHL treated with Bv-AVEPC have a higher rate of early response (determined by fludeoxyglucose F 18 [FDG]-positron emission tomography [PET]) and a reduction in protocol directed radiation therapy (RT) compared to those treated with ABVE-PC.
II. To compare the rate of neuropathy (>= grade 3) among patients treated on the Bv-AVEPC (experimental arm) to patients treated on the ABVE-PC (standard arm).
EXPLORATORY OBJECTIVES:
I. To validate and compare the Childhood Hodgkin International Prognostic Score (CHIPS) to conventional Ann Arbor stage (stages II B with bulk, III B, IV A or B) in predicting outcome in high-risk childhood cHL.
II. To determine the incidence of preferentially expressed antigen in melanoma (PRAME) and testis-specific antigens in Epstein-Barr virus (EBV)- cHL tumors and the incidence of EBV antigens (Epstein-Barr nuclear antigen 1 [EBNA1], Epstein-Barr virus latent membrane protein 1 [LMP1], large multifunctional peptidase 2 [LMP2]) in EBV+ cHL tumors, with the goal of developing strategies to integrate cellular therapy into treatment for newly diagnosed high-risk cHL. (Biology) III. To incorporate qualitative visual FDG-PET into response-directed treatment algorithms and explore quantitative FDG-PET and computed tomography (CT) definitions of tumor burden and response for incorporation into next generation pediatric cHL risk-stratification schemes, exploring the extension of these algorithms to young adults. (Imaging) IV. To evaluate the reduction in normal tissue irradiation associated with the current treatment approach compared to the volume of historic involved field radiation therapy (IFRT) fields. (Radiation Therapy) V. To evaluate EFS and patterns of relapse following protocol-specified RT utilization and treatment volumes. (Radiation Therapy) VI. To characterize the extent of chemotherapy induced peripheral neuropathy (CIPN), as reported by patients and parent proxies, through serial administration of the Functional Assessment of Cancer Therapy-Gynecologic Oncology Group-Neurotoxicity (FACT-GOG-NTX). (Patient Reported Outcomes [PRO] of Peripheral Neuropathy and Health-Related Quality of Life) VII. To describe the Health-Related Quality of Life (HRQL) consequences of peripheral neuropathy over time by correlating total neuropathy scale scores with the individual items with the Child Health Ratings Inventories (CHRIs)-Global scale (e.g., physical health, pain, emotional functioning). (PRO of Peripheral Neuropathy and Health-Related Quality of Life) VIII. To perform a cross validation of the FACT-GOG-NTX with the Total Neuropathy Score-Pediatric Vincristine (TNS-PV) to determine the performance of both measures with the use of brentuximab vedotin in a limited institutional approach in children and adolescents with cHL. (PRO of Peripheral Neuropathy and Health-Related Quality of Life) IX. To assess the resource use and cost implications of Bv in combination with chemotherapy and radiotherapy (RT) for newly diagnosed high-risk cHL in children and young adults. (Economic) X. To estimate the risk of relapse among rapidly responding lesions (RRL) subjects that have at least one lesion that is Deauville 3 at PET 2. (Follow-up of Deauville score 3 lesions on FDG-PET imaging [confirmed by central imaging review]) XI. To characterize the pharmacokinetics of brentuximab vedotin in children < 13 years of age.
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
ARM I (ABVE-PC): Patients receive doxorubicin hydrochloride intravenously (IV) over on days 1-2, bleomycin sulfate IV or subcutaneously (SC) on days 1 and 8, vincristine sulfate IV on days 1 and 8, etoposide IV on days 1-3, prednisone orally (PO) twice daily (BID) or methylprednisolone IV on days 1-7, and cyclophosphamide IV on days 1 and 2.
ARM II (Bv-AVEPC): Patients receive brentuximab vedotin IV on day 1. Patients also receive doxorubicin hydrochloride, etoposide, prednisone or methylprednisolone, and cyclophosphamide as in Arm I and vincristine sulfate IV on day 8.
In both arms, treatment repeats every 21 days for 5 cycles in the absence of disease progression or unacceptable toxicity. Granulocyte simulating factor (GCSF) or equivalent is given on both arms.
After completion of study treatment, patients are followed up at 3, 6, 9, 12, 18, 24, 30, 36, and 48 months.
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 3
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Québec, Canadá, G1V 4G2
- CHU de Quebec-Centre Hospitalier de l'Universite Laval (CHUL)
-
-
Alberta
-
Calgary, Alberta, Canadá, T3B 6A8
- Alberta Children's Hospital
-
Edmonton, Alberta, Canadá, T6G 2B7
- University of Alberta Hospital
-
-
British Columbia
-
Vancouver, British Columbia, Canadá, V6H 3V4
- British Columbia Children's Hospital
-
-
Manitoba
-
Winnipeg, Manitoba, Canadá, R3E 0V9
- CancerCare Manitoba
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canadá, B3K 6R8
- IWK Health Centre
-
-
Ontario
-
Hamilton, Ontario, Canadá, L8N 3Z5
- McMaster Children's Hospital at Hamilton Health Sciences
-
Kingston, Ontario, Canadá, K7L 2V7
- Kingston Health Sciences Centre
-
London, Ontario, Canadá, N6A 5W9
- Children's Hospital
-
Ottawa, Ontario, Canadá, K1H 8L1
- Children's Hospital of Eastern Ontario
-
Toronto, Ontario, Canadá, M5G 1X8
- Hospital for Sick Children
-
-
Quebec
-
Montreal, Quebec, Canadá, H3H 1P3
- The Montreal Children's Hospital of the MUHC
-
Montreal, Quebec, Canadá, H3T 1C5
- Centre Hospitalier Universitaire Sainte-Justine
-
-
Saskatchewan
-
Saskatoon, Saskatchewan, Canadá, S7N 4H4
- Saskatoon Cancer Centre
-
-
-
-
Alabama
-
Birmingham, Alabama, Estados Unidos, 35233
- Children's Hospital of Alabama
-
Mobile, Alabama, Estados Unidos, 36604
- USA Health Strada Patient Care Center
-
-
Alaska
-
Anchorage, Alaska, Estados Unidos, 99508
- Providence Alaska Medical Center
-
-
Arizona
-
Mesa, Arizona, Estados Unidos, 85202
- Banner Children's at Desert
-
Phoenix, Arizona, Estados Unidos, 85016
- Phoenix Childrens Hospital
-
Tucson, Arizona, Estados Unidos, 85719
- Banner University Medical Center - Tucson
-
-
Arkansas
-
Little Rock, Arkansas, Estados Unidos, 72202-3591
- Arkansas Children's Hospital
-
-
California
-
Downey, California, Estados Unidos, 90242
- Kaiser Permanente Downey Medical Center
-
Duarte, California, Estados Unidos, 91010
- City of Hope Comprehensive Cancer Center
-
Loma Linda, California, Estados Unidos, 92354
- Loma Linda University Medical Center
-
Long Beach, California, Estados Unidos, 90806
- Miller Children's and Women's Hospital Long Beach
-
Los Angeles, California, Estados Unidos, 90048
- Cedars-Sinai Medical Center
-
Los Angeles, California, Estados Unidos, 90027
- Children's Hospital Los Angeles
-
Madera, California, Estados Unidos, 93636
- Valley Children's Hospital
-
Oakland, California, Estados Unidos, 94611
- Kaiser Permanente-Oakland
-
Orange, California, Estados Unidos, 92868
- Children's Hospital of Orange County
-
Sacramento, California, Estados Unidos, 95816
- Sutter Medical Center Sacramento
-
Sacramento, California, Estados Unidos, 95817
- University of California Davis Comprehensive Cancer Center
-
San Diego, California, Estados Unidos, 92123
- Rady Children's Hospital - San Diego
-
San Diego, California, Estados Unidos, 92134
- Naval Medical Center -San Diego
-
Santa Barbara, California, Estados Unidos, 93102
- Santa Barbara Cottage Hospital
-
Torrance, California, Estados Unidos, 90502
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
-
-
Colorado
-
Aurora, Colorado, Estados Unidos, 80045
- Children's Hospital Colorado
-
Denver, Colorado, Estados Unidos, 80218
- Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center
-
-
Connecticut
-
Hartford, Connecticut, Estados Unidos, 06106
- Connecticut Children's Medical Center
-
New Haven, Connecticut, Estados Unidos, 06520
- Yale University
-
-
Delaware
-
Wilmington, Delaware, Estados Unidos, 19803
- Alfred I duPont Hospital for Children
-
-
District of Columbia
-
Washington D.C., District of Columbia, Estados Unidos, 20010
- Children's National Medical Center
-
Washington D.C., District of Columbia, Estados Unidos, 20007
- MedStar Georgetown University Hospital
-
-
Florida
-
Fort Lauderdale, Florida, Estados Unidos, 33316
- Broward Health Medical Center
-
Fort Myers, Florida, Estados Unidos, 33908
- Golisano Children's Hospital of Southwest Florida
-
Gainesville, Florida, Estados Unidos, 32610
- UF Health Cancer Institute - Gainesville
-
Hollywood, Florida, Estados Unidos, 33021
- Memorial Regional Hospital/Joe DiMaggio Children's Hospital
-
Jacksonville, Florida, Estados Unidos, 32207
- Nemours Children's Clinic-Jacksonville
-
Miami, Florida, Estados Unidos, 33155
- Nicklaus Children's Hospital
-
Miami, Florida, Estados Unidos, 33136
- University of Miami Miller School of Medicine-Sylvester Cancer Center
-
Miami, Florida, Estados Unidos, 33176
- Miami Cancer Institute
-
Orlando, Florida, Estados Unidos, 32827
- Nemours Children's Hospital
-
Orlando, Florida, Estados Unidos, 32803
- AdventHealth Orlando
-
Orlando, Florida, Estados Unidos, 32806
- Arnold Palmer Hospital for Children
-
Pensacola, Florida, Estados Unidos, 32504
- Nemours Children's Clinic - Pensacola
-
St. Petersburg, Florida, Estados Unidos, 33701
- Johns Hopkins All Children's Hospital
-
Tampa, Florida, Estados Unidos, 33606
- Tampa General Hospital
-
Tampa, Florida, Estados Unidos, 33607
- Saint Joseph's Hospital/Children's Hospital-Tampa
-
West Palm Beach, Florida, Estados Unidos, 33407
- Saint Mary's Medical Center
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30329
- Children's Healthcare of Atlanta - Arthur M Blank Hospital
-
Augusta, Georgia, Estados Unidos, 30912
- Augusta University Medical Center
-
Savannah, Georgia, Estados Unidos, 31404
- Memorial Health University Medical Center
-
-
Hawaii
-
Honolulu, Hawaii, Estados Unidos, 96826
- Kapiolani Medical Center for Women and Children
-
-
Idaho
-
Boise, Idaho, Estados Unidos, 83712
- Saint Luke's Cancer Institute - Boise
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60637
- University of Chicago Comprehensive Cancer Center
-
Chicago, Illinois, Estados Unidos, 60612
- University of Illinois
-
Chicago, Illinois, Estados Unidos, 60611
- Lurie Children's Hospital-Chicago
-
Maywood, Illinois, Estados Unidos, 60153
- Loyola University Medical Center
-
Oak Lawn, Illinois, Estados Unidos, 60453
- Advocate Children's Hospital-Oak Lawn
-
Park Ridge, Illinois, Estados Unidos, 60068
- Advocate Children's Hospital-Park Ridge
-
Peoria, Illinois, Estados Unidos, 61637
- OSF Children's Hospital of Illinois
-
Springfield, Illinois, Estados Unidos, 62702
- Southern Illinois University School of Medicine
-
-
Indiana
-
Indianapolis, Indiana, Estados Unidos, 46202
- Riley Hospital for Children
-
Indianapolis, Indiana, Estados Unidos, 46260
- Ascension Saint Vincent Indianapolis Hospital
-
-
Iowa
-
Des Moines, Iowa, Estados Unidos, 50309
- Blank Children's Hospital
-
Iowa City, Iowa, Estados Unidos, 52242
- University of Iowa/Holden Comprehensive Cancer Center
-
-
Kentucky
-
Lexington, Kentucky, Estados Unidos, 40536
- University of Kentucky/Markey Cancer Center
-
Louisville, Kentucky, Estados Unidos, 40202
- Norton Children's Hospital
-
-
Louisiana
-
New Orleans, Louisiana, Estados Unidos, 70121
- Ochsner Medical Center Jefferson
-
New Orleans, Louisiana, Estados Unidos, 70118
- Children's Hospital New Orleans
-
-
Maine
-
Bangor, Maine, Estados Unidos, 04401
- Eastern Maine Medical Center
-
-
Maryland
-
Baltimore, Maryland, Estados Unidos, 21287
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
Baltimore, Maryland, Estados Unidos, 21215
- Sinai Hospital of Baltimore
-
Baltimore, Maryland, Estados Unidos, 21201
- University of Maryland/Greenebaum Cancer Center
-
Bethesda, Maryland, Estados Unidos, 20889-5600
- Walter Reed National Military Medical Center
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02111
- Tufts Children's Hospital
-
Springfield, Massachusetts, Estados Unidos, 01199
- Baystate Medical Center
-
Worcester, Massachusetts, Estados Unidos, 01655
- UMass Memorial Medical Center - University Campus
-
-
Michigan
-
Ann Arbor, Michigan, Estados Unidos, 48109
- C S Mott Children's Hospital
-
Detroit, Michigan, Estados Unidos, 48201
- Wayne State University/Karmanos Cancer Institute
-
Detroit, Michigan, Estados Unidos, 48236
- Henry Ford Health Saint John Hospital
-
East Lansing, Michigan, Estados Unidos, 48823
- Michigan State University
-
Flint, Michigan, Estados Unidos, 48503
- Hurley Medical Center
-
Grand Rapids, Michigan, Estados Unidos, 49503
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital
-
Kalamazoo, Michigan, Estados Unidos, 49007
- Bronson Methodist Hospital
-
Royal Oak, Michigan, Estados Unidos, 48073
- Corewell Health Children's
-
-
Minnesota
-
Minneapolis, Minnesota, Estados Unidos, 55404
- Children's Hospitals and Clinics of Minnesota - Minneapolis
-
Minneapolis, Minnesota, Estados Unidos, 55455
- University of Minnesota/Masonic Cancer Center
-
Rochester, Minnesota, Estados Unidos, 55905
- Mayo Clinic in Rochester
-
-
Mississippi
-
Jackson, Mississippi, Estados Unidos, 39216
- University of Mississippi Medical Center
-
-
Missouri
-
Columbia, Missouri, Estados Unidos, 65212
- University of Missouri Children's Hospital
-
Kansas City, Missouri, Estados Unidos, 64108
- Children's Mercy Hospitals and Clinics
-
St Louis, Missouri, Estados Unidos, 63110
- Washington University School of Medicine
-
St Louis, Missouri, Estados Unidos, 63141
- Mercy Hospital Saint Louis
-
St Louis, Missouri, Estados Unidos, 63104
- Cardinal Glennon Children's Medical Center
-
-
Nebraska
-
Omaha, Nebraska, Estados Unidos, 68198
- University of Nebraska Medical Center
-
Omaha, Nebraska, Estados Unidos, 68114
- Children's Hospital and Medical Center of Omaha
-
-
Nevada
-
Las Vegas, Nevada, Estados Unidos, 89144
- Summerlin Hospital Medical Center
-
Las Vegas, Nevada, Estados Unidos, 89109
- Sunrise Hospital and Medical Center
-
Las Vegas, Nevada, Estados Unidos, 89135
- Alliance for Childhood Diseases/Cure 4 the Kids Foundation
-
Las Vegas, Nevada, Estados Unidos, 89102
- University Medical Center of Southern Nevada
-
-
New Hampshire
-
Lebanon, New Hampshire, Estados Unidos, 03756
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
-
-
New Jersey
-
Hackensack, New Jersey, Estados Unidos, 07601
- Hackensack University Medical Center
-
Morristown, New Jersey, Estados Unidos, 07960
- Morristown Medical Center
-
New Brunswick, New Jersey, Estados Unidos, 08901
- Saint Peter's University Hospital
-
New Brunswick, New Jersey, Estados Unidos, 08903
- Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital
-
Newark, New Jersey, Estados Unidos, 07112
- Newark Beth Israel Medical Center
-
Paterson, New Jersey, Estados Unidos, 07503
- Saint Joseph's Regional Medical Center
-
-
New Mexico
-
Albuquerque, New Mexico, Estados Unidos, 87106
- University of New Mexico Cancer Center
-
-
New York
-
Albany, New York, Estados Unidos, 12208
- Albany Medical Center
-
Buffalo, New York, Estados Unidos, 14263
- Roswell Park Cancer Institute
-
Mineola, New York, Estados Unidos, 11501
- NYU Langone Hospital - Long Island
-
New Hyde Park, New York, Estados Unidos, 11040
- The Steven and Alexandra Cohen Children's Medical Center of New York
-
New York, New York, Estados Unidos, 10065
- Memorial Sloan Kettering Cancer Center
-
New York, New York, Estados Unidos, 10029
- Mount Sinai Hospital
-
New York, New York, Estados Unidos, 10032
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
-
New York, New York, Estados Unidos, 10065
- NYP/Weill Cornell Medical Center
-
New York, New York, Estados Unidos, 10016
- Laura and Isaac Perlmutter Cancer Center at NYU Langone
-
Rochester, New York, Estados Unidos, 14642
- University of Rochester
-
Stony Brook, New York, Estados Unidos, 11794
- Stony Brook University Medical Center
-
Syracuse, New York, Estados Unidos, 13210
- State University of New York Upstate Medical University
-
The Bronx, New York, Estados Unidos, 10467
- Montefiore Medical Center - Moses Campus
-
-
North Carolina
-
Asheville, North Carolina, Estados Unidos, 28801
- Mission Hospital
-
Chapel Hill, North Carolina, Estados Unidos, 27599
- UNC Lineberger Comprehensive Cancer Center
-
Charlotte, North Carolina, Estados Unidos, 28203
- Carolinas Medical Center/Levine Cancer Institute
-
Charlotte, North Carolina, Estados Unidos, 28204
- Novant Health Presbyterian Medical Center
-
Durham, North Carolina, Estados Unidos, 27710
- Duke University Medical Center
-
Greenville, North Carolina, Estados Unidos, 27834
- East Carolina University
-
Winston-Salem, North Carolina, Estados Unidos, 27157
- Wake Forest University Health Sciences
-
-
North Dakota
-
Fargo, North Dakota, Estados Unidos, 58122
- Sanford Broadway Medical Center
-
-
Ohio
-
Akron, Ohio, Estados Unidos, 44308
- Children's Hospital Medical Center of Akron
-
Cincinnati, Ohio, Estados Unidos, 45229
- Cincinnati Children's Hospital Medical Center
-
Cleveland, Ohio, Estados Unidos, 44195
- Cleveland Clinic Foundation
-
Cleveland, Ohio, Estados Unidos, 44106
- Rainbow Babies and Childrens Hospital
-
Columbus, Ohio, Estados Unidos, 43205
- Nationwide Children's Hospital
-
Dayton, Ohio, Estados Unidos, 45404
- Dayton Children's Hospital
-
Toledo, Ohio, Estados Unidos, 43606
- ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Estados Unidos, 73104
- University of Oklahoma Health Sciences Center
-
-
Oregon
-
Portland, Oregon, Estados Unidos, 97239
- Oregon Health and Science University
-
Portland, Oregon, Estados Unidos, 97227
- Legacy Emanuel Children's Hospital
-
-
Pennsylvania
-
Allentown, Pennsylvania, Estados Unidos, 18103
- Lehigh Valley Hospital-Cedar Crest
-
Bethlehem, Pennsylvania, Estados Unidos, 18017
- Lehigh Valley Hospital - Muhlenberg
-
Danville, Pennsylvania, Estados Unidos, 17822
- Geisinger Medical Center
-
Hershey, Pennsylvania, Estados Unidos, 17033
- Penn State Children's Hospital
-
Philadelphia, Pennsylvania, Estados Unidos, 19104
- Children's Hospital of Philadelphia
-
Philadelphia, Pennsylvania, Estados Unidos, 19134
- Saint Christopher's Hospital for Children
-
Pittsburgh, Pennsylvania, Estados Unidos, 15224
- Children's Hospital of Pittsburgh of UPMC
-
-
Rhode Island
-
Providence, Rhode Island, Estados Unidos, 02903
- Rhode Island Hospital
-
-
South Carolina
-
Charleston, South Carolina, Estados Unidos, 29425
- Medical University of South Carolina
-
Columbia, South Carolina, Estados Unidos, 29203
- Prisma Health Richland Hospital
-
Greenville, South Carolina, Estados Unidos, 29605
- BI-LO Charities Children's Cancer Center
-
-
South Dakota
-
Sioux Falls, South Dakota, Estados Unidos, 57117-5134
- Sanford USD Medical Center - Sioux Falls
-
-
Tennessee
-
Chattanooga, Tennessee, Estados Unidos, 37403
- T C Thompson Children's Hospital
-
Knoxville, Tennessee, Estados Unidos, 37916
- East Tennessee Childrens Hospital
-
Nashville, Tennessee, Estados Unidos, 37232
- Vanderbilt University/Ingram Cancer Center
-
Nashville, Tennessee, Estados Unidos, 37203
- The Children's Hospital at TriStar Centennial
-
-
Texas
-
Austin, Texas, Estados Unidos, 78723
- Dell Children's Medical Center of Central Texas
-
Corpus Christi, Texas, Estados Unidos, 78411
- Driscoll Children's Hospital
-
Dallas, Texas, Estados Unidos, 75390
- UT Southwestern/Simmons Cancer Center-Dallas
-
Dallas, Texas, Estados Unidos, 75230
- Medical City Dallas Hospital
-
El Paso, Texas, Estados Unidos, 79905
- El Paso Children's Hospital
-
Fort Worth, Texas, Estados Unidos, 76104
- Cook Children's Medical Center
-
Houston, Texas, Estados Unidos, 77030
- UT MD Anderson Cancer Center
-
Houston, Texas, Estados Unidos, 77030
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
-
Lubbock, Texas, Estados Unidos, 79410
- Covenant Children's Hospital
-
Lubbock, Texas, Estados Unidos, 79415
- UMC Cancer Center / UMC Health System
-
San Antonio, Texas, Estados Unidos, 78229
- University of Texas Health Science Center at San Antonio
-
San Antonio, Texas, Estados Unidos, 78207
- Children's Hospital of San Antonio
-
San Antonio, Texas, Estados Unidos, 78229
- Methodist Children's Hospital of South Texas
-
Temple, Texas, Estados Unidos, 76508
- Scott and White Memorial Hospital
-
-
Utah
-
Salt Lake City, Utah, Estados Unidos, 84113
- Primary Children's Hospital
-
-
Vermont
-
Burlington, Vermont, Estados Unidos, 05405
- University of Vermont and State Agricultural College
-
-
Virginia
-
Charlottesville, Virginia, Estados Unidos, 22908
- University of Virginia Cancer Center
-
Falls Church, Virginia, Estados Unidos, 22042
- Inova Fairfax Hospital
-
Norfolk, Virginia, Estados Unidos, 23507
- Children's Hospital of The King's Daughters
-
Richmond, Virginia, Estados Unidos, 23298
- VCU Massey Comprehensive Cancer Center
-
-
Washington
-
Seattle, Washington, Estados Unidos, 98105
- Seattle Children's Hospital
-
Spokane, Washington, Estados Unidos, 99204
- Providence Sacred Heart Medical Center and Children's Hospital
-
Tacoma, Washington, Estados Unidos, 98405
- Mary Bridge Children's Hospital and Health Center
-
Tacoma, Washington, Estados Unidos, 98431
- Madigan Army Medical Center
-
-
West Virginia
-
Charleston, West Virginia, Estados Unidos, 25304
- Vandalia Health/CAMC Institute for Academic Medicine
-
Morgantown, West Virginia, Estados Unidos, 26506
- West Virginia University Healthcare
-
-
Wisconsin
-
Green Bay, Wisconsin, Estados Unidos, 54301
- Saint Vincent Hospital Cancer Center Green Bay
-
Madison, Wisconsin, Estados Unidos, 53792
- University of Wisconsin Carbone Cancer Center - University Hospital
-
Marshfield, Wisconsin, Estados Unidos, 54449
- Marshfield Medical Center-Marshfield
-
Milwaukee, Wisconsin, Estados Unidos, 53226
- Children's Hospital of Wisconsin
-
-
-
-
-
Caguas, Puerto Rico, 00726
- HIMA San Pablo Oncologic Hospital
-
San Juan, Puerto Rico, 00926
- University Pediatric Hospital
-
San Juan, Puerto Rico, 00912
- San Jorge Children's Hospital
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
-
Patients with newly diagnosed, pathologically confirmed cHL meeting one of the following Ann Arbor stages are eligible:
-
Stage IIB with bulk
-
Stage IIIB
-
Stage IVA
-
Stage IVB
- If study eligibility by staging is uncertain, consultation with Imaging and Radiation Oncology Core (IROC) Rhode Island (RI) may be obtained prior to study enrollment
-
-
Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70 mL/min/1.73 m^2 or a serum creatinine based on age/gender as follows (performed within 14 days prior to enrollment):
- 2 to < 6 years: male 0.8 mg/dL, female 0.8 mg/dL
- 6 to < 10 years: male 1 mg/dL, female 1 mg/dL
- 10 to < 13 years: male 1.2 mg/dL, female 1.2 mg/dL
- 13 to < 16 years: male 1.5 mg/dL, female 1.4 mg/dL
- >= 16 years: male 1.7 mg/dL, female 1.4 mg/dL
-
Total bilirubin =< 1.5 x upper limit of normal (ULN) for age (performed within 14 days prior to enrollment)
-
Serum glutamic oxaloacetic transaminase (SGOT) (aspartate transaminase [AST]) or serum glutamate pyruvate transaminase (SGPT) (alanine transaminase [ALT]) < 2.5 x upper limit of normal (ULN) for age (performed within 14 days prior to enrollment)
-
Shortening fraction of >= 27% by echocardiogram, or ejection fraction of >= 50% by radionuclide angiogram
-
Forced expiratory volume in 1 second (FEV1)/forced vital capacity (FVC) > 60% by pulmonary function test (PFT), unless due to large mediastinal mass from Hodgkin lymphoma (HL)
-
For children who are unable to cooperate for PFTs, the criteria are: no evidence of dyspnea at rest, no exercise intolerance, and a pulse oximetry reading of > 92% on room air
-
All patients and/or their parents or legal guardians must sign a written informed consent
-
All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met
Exclusion Criteria:
- Patients with nodular lymphocyte-predominant HL
- Patients with an immunodeficiency that existed prior to diagnosis, such as primary immunodeficiency syndromes, organ transplant recipients and children on current systemic immunosuppressive agents are not eligible
- Patients who are pregnant; (since fetal toxicities and teratogenic effects have been noted for several of the study drugs, a negative pregnancy test is required for female patients of childbearing potential)
- Lactating females who plan to breastfeed
- Sexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of their study participation and for 30 days after the last dose of chemotherapy
- Patients known to be positive for human immunodeficiency virus (HIV) are not eligible
- Patients who have received any previous chemotherapy or radiation therapy are not eligible
- Patients who received systemic corticosteroids within 28 days of enrollment on this protocol, except as specified, are not eligible
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Único
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Comparador activo: Arm I (ABVE-PC)
Patients receive doxorubicin hydrochloride IV over on days 1-2, bleomycin sulfate IV or SC on days 1 and 8, vincristine sulfate IV on days 1 and 8, etoposide IV on days 1-3, prednisone orally PO BID or methylprednisolone IV on days 1-7, and cyclophosphamide IV on days 1 and 2. Treatment repeats every 21 days for 5 cycles in the absence of disease progression or unacceptable toxicity. |
Correlative studies Ancillary studies
Otros nombres:
Given IV
Otros nombres:
Given IV
Otros nombres:
Given PO
Otros nombres:
Given IV
Otros nombres:
Ancillary studies Given IV
Otros nombres:
Correlative studies Given IV or SC
Otros nombres:
Given IV
Otros nombres:
|
|
Experimental: ARM II (Bv-AVEPC)
Patients receive brentuximab vedotin IV on day 1. Patients also receive doxorubicin hydrochloride, etoposide, prednisone or methylprednisolone, and cyclophosphamide as in Arm I and vincristine sulfate IV on day 8. Treatment repeats every 21 days for 5 cycles in the absence of disease progression or unacceptable toxicity. |
Correlative studies Ancillary studies
Otros nombres:
Given IV
Otros nombres:
Given IV
Otros nombres:
Given PO
Otros nombres:
Given IV
Otros nombres:
Ancillary studies Given IV
Otros nombres:
Given IV
Otros nombres:
Correlative studies Given IV
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Event Free Survival (EFS), Where Events Include Disease Progression or Relapse, Second Malignancy, or Death
Periodo de tiempo: Up to 48 months after the last enrollment
|
Primary analysis will be based 1-sided log rank test comparison of EFS curves between the 2 randomized arms per intention-to-treat principle. Progression is defined as an ≥50% increase of in the product of the perpendicular diameters of any of the involved nodes or nodal masses or focal organ lesions in sites that were persistently PET positive; or recurrent PET positive lesions (Deauville 4, 5) in sites that had previously been PET negative regardless of change of size, as was the development of new PET avid measurable lesion(s) >1.5cm in any axis, or new sites of assessable disease. Relapse is defined in patients who achieved a prior CR but subsequently has an increase of ≥50% of the PPD in prior nodal or extranodal sites in a recurrently PET positive lesion(s), or the development of new measurable lesion(s) >1.5cm in any axis, or new sites of assessable disease. Second malignancy is defined based on report of a cancer that is not considered to be classic Hodgkin Lymphoma. |
Up to 48 months after the last enrollment
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Percentages of Patients With Early Response Defined as no Slow Responding Lesions (SRL) and no Progressive Disease (PD) at Any Disease Sites Determined by Positron Emission Tomography (PET) Per Deauville Criteria Through Central Review
Periodo de tiempo: After 42 days of chemotherapy
|
The percentages of patients (with available PET scan) with no SRL and no PD will be compared between the two randomized arms to see if brentuximab vedotin in the chemotherapy backbone of doxorubicin hydrochloride, vincristine sulfate, etoposide, prednisone and cyclophosphamide (Bv-AVEPC) arm has a higher rate of early response compared to doxorubicin hydrochloride, bleomycin sulfate, vincristine sulfate, etoposide, prednisone, and cyclophosphamide (ABVE-PC) arm. Two-sample Z test of proportions at 1-sided alpha level of 0.05 will be used for these comparisons. |
After 42 days of chemotherapy
|
|
Percentages of Patients Experiencing Grade 3+ Peripheral Neuropathy Assessed by Modified Balis Scale
Periodo de tiempo: From the enrollment of the patient to the time of analysis or the last follow-up; an average of 3.6 years.
|
The percentages of patients experiencing grade 3+ peripheral neuropathy assessed by the treating clinician using the modified Balis scale. The "Modified Balis scale of Pediatric Neuropathy" allows clinicians to assign a score for sensory or motor neuropathy symptoms separately. Scores range from 1 to 4 with 1 being the least symptomatic state and 4 indicating a severe debility. The percentages of patients (with a score >/=3) will be compared between the 2 arms by two-sample Z test at 1-sided alpha level of 0.05. |
From the enrollment of the patient to the time of analysis or the last follow-up; an average of 3.6 years.
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Childhood International Prognostic Score (CHIPS) Score
Periodo de tiempo: Baseline
|
CHIPS will be computed for all patients and summarized by descriptive statistics. Will examine the association between CHIPS and early response by cross-tabulations and Chi-square tests within each arm separately, as well as logistic regression model where early response is the outcome variable and CHIPS the predictor variable combining the 2 arms with adjustment for randomized chemotherapy. |
Baseline
|
|
Dose of Radiation Received by Normal Tissues Following Chemotherapy on Either Study Arm
Periodo de tiempo: Up to 48 months
|
Descriptive statistics will be used to summarize RT doses received by normal tissues on this study. Two-sample t-test will be used to compare the doses received on this study to those on prior studies. |
Up to 48 months
|
|
Efficacy of Involved Site Radiotherapy (ISRT) by Analyzing the Event-free Survival of Patients Treated With Response-adapted ISRT and by Evaluating Patterns of Relapse Following ISRT
Periodo de tiempo: Up to 3 years
|
EFS for patients on each arm as well as those receiving ISRT or those with slow early response (SER) on each arm will be estimated. One-sample log rank test will be used to compare the observed EFS to the assumed baseline of 82% at 3 years to see if the observed EFS is significantly lower than the projection in these subsets. |
Up to 3 years
|
|
Risk of Relapse Among RRL Subjects That Have at Least One Lesion That is Deauville 3 at PET 2
Periodo de tiempo: Up to 48 months after the last enrollment
|
The risk of relapse for cases that are RRL, but have Deauville 3 lesions, will be compared to those that are classified as complete metabolic response at PET2 with solely Deauville 1 or 2 lesions with K-sample test. |
Up to 48 months after the last enrollment
|
|
Pharmacokinetic (PK) Analyses
Periodo de tiempo: Pre-dose and end of infusion on day 1, days 2, 3, 8, and 15 of cycle 4 and pre-dose on day 1 and day 22 of cycle 5 (each cycle = 21 days)
|
PK concentration time profile will be evaluated. |
Pre-dose and end of infusion on day 1, days 2, 3, 8, and 15 of cycle 4 and pre-dose on day 1 and day 22 of cycle 5 (each cycle = 21 days)
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Sharon M Castellino, Children's Oncology Group
Publicaciones y enlaces útiles
Publicaciones Generales
- Castellino SM, Pei Q, Parsons SK, Hodgson D, McCarten K, Horton T, Cho S, Wu Y, Punnett A, Dave H, Henderson TO, Hoppe BS, Charpentier AM, Keller FG, Kelly KM. Brentuximab Vedotin with Chemotherapy in Pediatric High-Risk Hodgkin's Lymphoma. N Engl J Med. 2022 Nov 3;387(18):1649-1660. doi: 10.1056/NEJMoa2206660.
- Castellino SM, Giulino-Roth L, Harker-Murray P, Kahn JM, Forlenza C, Cho S, Hoppe B, Parsons SK, Kelly KM; COG Hodgkin Lymphoma Committee. Children's Oncology Group's 2023 blueprint for research: Hodgkin lymphoma. Pediatr Blood Cancer. 2023 Sep;70 Suppl 6(Suppl 6):e30580. doi: 10.1002/pbc.30580. Epub 2023 Jul 28.
- Tie X, Shin M, Lee C, Perlman SB, Huemann Z, Weisman AJ, Castellino SM, Kelly KM, McCarten KM, Alazraki AL, Hu J, Cho SY, Bradshaw TJ. Automatic Quantification of Serial PET/CT Images for Pediatric Hodgkin Lymphoma Using a Longitudinally Aware Segmentation Network. Radiol Artif Intell. 2025 May;7(3):e240229. doi: 10.1148/ryai.240229.
- Pabari R, McCarten K, Flerlage J, Lai H, Mauz-Korholz C, Dieckmann K, Palese M, Kaste S, Castellino SM, Kelly KM, Stoevesandt D, Kurch L. Hodgkin lymphoma involving the extra-axial CNS: an AHOD1331, PHL-C1, and PHL-C2 report from the COG and EuroNet-PHL. Blood Adv. 2024 Sep 24;8(18):4856-4865. doi: 10.1182/bloodadvances.2023012346.
- Williams AM, Rodday AM, Pei Q, Henderson TO, Keller FG, Punnett A, Kelly KM, Castellino SM, Parsons SK. Longitudinal Health-Related Quality of Life Among Patients With High-Risk Pediatric Hodgkin Lymphoma Treated on the Children's Oncology Group AHOD 1331 Study. J Clin Oncol. 2024 Oct;42(28):3330-3338. doi: 10.1200/JCO.24.00038. Epub 2024 Jul 26.
- Parsons SK, Rodday AM, Pei Q, Keller FG, Wu Y, Henderson TO, Cella D, Kelly KM, Castellino SM. Performance of the FACT-GOG-Ntx to assess chemotherapy-induced peripheral neuropathy (CIPN) in pediatric high risk Hodgkin lymphoma: report from the Children's Oncology Group AHOD 1331 study. J Patient Rep Outcomes. 2023 Nov 10;7(1):113. doi: 10.1186/s41687-023-00653-0.
- Hoppe BS, McCarten KM, Pei Q, Kessel S, Alazraki A, Mhlanga JC, Lai HA, Eutsler E, Hodgson DC, Roberts KB, Charpentier AM, Keller FG, Voss SD, Wu Y, Cho SY, Kelly KM, Castellino SM. Importance of Central Imaging Review in a Pediatric Hodgkin Lymphoma Trial Using Positron Emission Tomography Response Adapted Radiation Therapy. Int J Radiat Oncol Biol Phys. 2023 Aug 1;116(5):1025-1030. doi: 10.1016/j.ijrobp.2023.02.020. Epub 2023 Mar 2.
- Williams AM, Rodday AM, Renfro LA, Wu Y, Henderson TO, Keller FG, Punnett A, Hodgson D, Kelly KM, Castellino SM, Parsons SK. Group-based trajectories of health-related quality of life among pediatric patients with high-risk Hodgkin lymphoma. J Natl Cancer Inst. 2025 Oct 1;117(10):2112-2119. doi: 10.1093/jnci/djaf197.
- Toner K, Renfro LA, Dave H, Pezzella G, Pei Q, Giulino-Roth L, Horton T, Keller FG, Kelly KM, Castellino SM, Bollard CM. Tumor-specific immune responses and biomarkers in pediatric patients with high-risk Hodgkin lymphoma. Blood Adv. 2026 Jan 13;10(1):183-191. doi: 10.1182/bloodadvances.2025016797.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimado)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Péptidos
- Aminoácidos, péptidos y proteínas
- Oligopéptidos
- Proteínas
- Químicos orgánicos
- Compuestos heterocíclicos
- Compuestos heterocíclicos, 2 anillos
- Compuestos heterocíclicos, anillo fusionado
- Hidrocarburos
- Hidrocarburos, cíclico
- Carbohidratos
- Alcaloides
- Podoflotoxina
- Tetrahidronaftalenos
- Naftalenos
- Hidrocarburos aromáticos policíclicos
- Hidrocarburos, aromáticos
- Compuestos policíclicos
- Glucósidos
- Glucósidos
- Indoles
- Anticuerpos, monoclonales, humanizados
- Anticuerpos, monoclonal
- Anticuerpos
- Inmunoglobulinas
- Inmunoproteínas
- Proteínas de la sangre
- Globulinas séricas
- Globulinas
- Espierra
- Embarazos
- Esteroides
- Compuestos de anillo fusionado
- Mostaza de fosforamida
- Compuestos de mostaza de nitrógeno
- Compuestos de mostaza
- Hidrocarburos, halogenados
- Fosforamidas
- Compuestos organofosforados
- Esparrazadienetrioles
- Madreadiediols
- Alcaloides de Vinca
- Alcaloides de triptamina de secologanina
- Alcaloides de indol
- Indolizidinas
- Indolizinas
- Antraciclinas
- Naftacenos
- Aminoglucósidos
- Glucoconjugados
- Daunorrubicina
- Glucopéptidos
- Prednisolona
- Brentuximab vedotina
- Prednisona
- Ciclofosfamida
- Etopósido
- Doxorrubicina
- Vincristina
- Metilprednisolona
- Bleomicina
- deltacorteno
- predilideno
- exifono
- Medrol Veriderm
Otros números de identificación del estudio
- NCI-2014-01223
- U10CA180886 (Subvención/contrato del NIH de EE. UU.)
- NCI-2014-01223 (Identificador de registro: CTRP (Clinical Trial Reporting Program))
- s15-00950
- AHOD1331 (Otro identificador: CTEP)
- AHOD1331 (Otro identificador: Children's Oncology Group)
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .